Endogenous Cushing's syndrome during pregnancy

Rev Endocr Metab Disord. 2023 Feb;24(1):23-38. doi: 10.1007/s11154-022-09731-y. Epub 2022 Jun 7.

Abstract

Endogenous Cushing's syndrome (CS) is rare during pregnancy, probably because hypercortisolism induces anovulation and infertility. To date, slightly above 200 cases have been reported in the literature. The most frequent etiology of CS diagnosed during gestation is from primary adrenal causes, namely adrenal adenomas and an entity called pregnancy-induced CS. The latter can be secondary to the aberrant adrenal expression of luteinizing hormone/human chorionic gonadotropin receptor (LHCGR) in the adrenal lesions. Diagnosis of CS during pregnancy is extremely challenging, as a consequence of the physiologic hypercortisolism normally present during pregnancy. Assessment of excess cortisol production tests should be interpreted cautiously using adapted upper limits of normal criteria for pregnant patients and a high index of suspicion is required for diagnosis. Imaging is also limited due to high risk of radiation exposure with computed tomography and teratogenicity with contrast agents. The optimal treatment strategy is surgical resection of adrenal adenoma or pituitary adenoma, ideally before 24 weeks of gestation to reduce the risk of maternal and fetal complications. In mild cases, surgery can be postponed until after delivery and treatment should focus on controlling metabolic complications of hypercortisolism, such as hypertension and dysglycemia. Maternal and fetal outcomes of excess cortisol exposure, except fetal loss, are not readily improved by successful treatment of hypercortisolism.

Keywords: Adrenal tumors/hyperplasia; Cushing’s syndrome; Fetal outcomes; LHCG receptor; Pregnancy.

Publication types

  • Review

MeSH terms

  • Adenoma*
  • Cushing Syndrome* / diagnosis
  • Cushing Syndrome* / etiology
  • Female
  • Humans
  • Hydrocortisone
  • Hypertension*
  • Pregnancy

Substances

  • Hydrocortisone